March 7, 2002
Caliper Technologies Corp.
Daniel L. Kisner, M.D.
President and CEO
Lab Performance Remains a Bottleneck
What is the history of your organization’s involvement in life sciences?
Kisner: In 1999, we established Caliper as a leader in lab-on-a-chip technology. We became the first microfluidic lab-on-a-chip company to commercialize products and the first to become publicly traded. The foundation for these important events was built five years ago by the company’s founders: Michael Knapp, Wally Parce, Calvin Chow, Larry Bock, and Mike Ramsey. Their knowledge and vision have enabled Caliper to become the vibrant, innovative, and competitive company it is today.
Today more than ever, research-based industries are faced with the challenge of transforming enormous volumes of raw data into important new discoveries. They are in a race to turn sequencing efforts into life-saving medicines—with the need never greater to conduct experiments with more efficiency and precision. Current laboratory systems can’t deliver the accuracy, productivity, or quality of information required to compete in today’s discovery arena. These limitations are creating bottlenecks in the research process.
What is your vision for the development of the life sciences market?
Kisner: We believe our LabChip® systems represent a revolutionary advance in laboratory experimentation. Our systems have the potential to expand the capabilities and improve the productivity of individual researchers and, on an institutional level, enable companies in multiple industries to perform the massive-scale experimentation they need to advance research and development. As a result, our LabChip technology has the potential to reduce the time and expense involved in the discovery and commercialization of new products.
What products and services does your company provide to the life sciences market?Kisner: The Agilent 2100 Bioanalyzer is a small, affordable system designed for the individual investigator. By integrating and accelerating sample handling, sample analysis, and data reporting in a bench-top LabChip® system, it effectively replaces labor-intensive gel electrophoresis while yielding higher-quality data. The 2100 Bioanalyzer’s advanced microfluidic technology requires only minuscule amounts of sample and reagents. With a few simple keystrokes, the system’s powerful software delivers quantitative digital results.
The Automated Microfluidics System 90 (AMS 90), sold directly by Caliper, automates DNA fragment analysis for laboratories that generate hundreds to thousands of samples per day. The AMS 90 couples a high degree of automation with exceptional data quality, rendering large-scale slab gel electrophoresis obsolete.
Return to main index page.